Common blood thinning drugs may reduce death risk in COVID-19

Credit: CC0 Public Domain

In a recent study, researchers found that patients given preventive blood-thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital with COVID-19 are less likely to die.

The study is published in The BMJ. One author is Christopher T Rentsch.

Some COVID deaths are believed to be due to blood clots developing in major veins and arteries.

Anticoagulants prevent blood clots from forming and have antiviral and potent anti-inflammatory properties, so might be particularly effective in patients with COVID-19, but results from previous studies have been inconclusive.

In the study, the team set out to estimate the effect of prophylactic anticoagulants on the risk of death and severe bleeding in patients with COVID-19.

Their findings were based on data from the United States Department of Veterans Affairs for 4,297 patients (average age 68 years; 93% men) admitted to hospital with COVID-19 between 1 March and 31 July 2020.

The researchers then followed these patients to see who died or experienced a serious bleeding event within 30 days of hospital admission.

A total of 3,627 (84.4%) of patients received prophylactic anticoagulation within 24 hours of admission and there were 622 deaths (14.5%) within 30 days.

The team found the death at 30 days was 14.3% among those who received prophylactic anticoagulation compared with 18.7% among those who did not.

This benefit seemed to be greater among patients not admitted to the intensive care unit (ICU) within 24 hours of hospital admission.

Receiving prophylactic anticoagulation was not linked to an increased risk of serious bleeding.

These findings provide strong real-world evidence to support guidelines recommending the use of prophylactic anticoagulation as an initial treatment for patients with COVID-19 on hospital admission.

Clinical trials are now underway to see if prophylactic anticoagulants could be an effective treatment for COVID-19.

If you care about COVID-19, please read studies about this anti-inflammatory drug could reduce COVID-19 death risk and findings of people with this health condition have high risk of severe COVID-19.

For more information about COVID-19 prevention and treatment, please see recent studies about COVID-19 combined with this health problem can increase death risk by 74% and results showing that new antiviral drug 10 times more effective against COVID-19.

Copyright © 2021 Knowridge Science Report. All rights reserved.